Seres Therapeutics (MCRB) Current Assets (2014 - 2026)

Seres Therapeutics has disclosed Current Assets across 13 years of filings, most recently posting $42.3 million for Q2 2026.

• In Q2 2026, Current Assets fell 13.02% year-over-year to $42.3 million; the TTM figure through Jun 2026 stood at $42.3 million (down 13.02% YoY), while the FY2025 annual figure was $49.4 million, up 27.67% from the prior year.
• Current Assets came in at $42.3 million for Q2 2026 at Seres Therapeutics, up from $31.8 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $263.2 million in Q1 2022 to a low of $31.8 million in Q1 2026.
• Average Current Assets over 5 years is $132.7 million, with a median of $132.7 million recorded in 2023.
• The largest YoY upside for Current Assets was 42.3% in 2024 against a maximum downside of 77.95% in 2024.
• Over 5 years, Current Assets stood at $194.8 million in 2022, then decreased by 9.94% to $175.4 million in 2023, then plunged by 77.95% to $38.7 million in 2024, then gained by 27.67% to $49.4 million in 2025, then fell by 14.23% to $42.3 million in 2026.
• Per Business Quant data, the three most recent Current Assets figures were $42.3 million in Q2 2026, $31.8 million in Q1 2026, and $49.4 million in Q4 2025.